{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:16:21Z","timestamp":1791411381083,"version":"4.3.3"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> This was a prospective phase II trial of rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD; considered one cycle) alternating every 21 days with rituximab plus high-dose methotrexate-cytarabine (considered one cycle) for a total of six to eight cycles. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Of 97 assessable patients, 97% responded, and 87% achieved a complete response (CR) or unconfirmed CR. With a median follow-up time of 40 months, the 3-year FFS and overall survival rates were 64% and 82%, respectively, without a plateau in the curves. For the subgroup of patients \u2264 65 years of age, the 3-year FFS rate was 73%. The principal toxicity was hematologic. Five patients died from acute toxicity. Four patients developed treatment-related myelodysplasia\/acute myelogenous leukemia, and three patients died while in remission from MCL. A total of eight treatment-related deaths (8%) occurred. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine is effective in untreated aggressive MCL. Toxicity is significant but expected. Because of the shorter FFS concurrent with significant toxicity in patients more than 65 years of age, this regimen is not recommended as standard therapy for this age subgroup. Larger prospective randomized studies are needed to define the role of this regimen in the treatment of MCL patients compared with existing and new treatment modalities. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.01.1825","type":"journal-article","created":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T00:44:35Z","timestamp":1126053875000},"page":"7013-7023","source":"Crossref","is-referenced-by-count":450,"title":["High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine"],"prefix":"10.1200","volume":"23","author":[{"given":"Jorge E.","family":"Romaguera","sequence":"first","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine R.","family":"Broglio","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Sarris","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam H.","family":"Dang","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Beasley","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth L.","family":"Katz","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Gagneja","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry I.","family":"Samuels","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando F.","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma\/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.00895.x"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1664"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070505"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"R13","unstructured":"Stanley KE: Prognostic factors for survival in patients with inoperative lung cancer. J Natl Cancer Inst 65:25,1980-32,"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Luthra R, Sarris AH, Hai S, et al: Real-time 5\u2032 \u2192 3\u2032 exonuclease-based PCR assay for the detection of the t(11;13)(q13;q32). Am J Clin Pathol 112:254,1999-530,","DOI":"10.1093\/ajcp\/112.4.524"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1309\/69EJ-RFM5-E976-BUTP"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc 35:185,1972-207,","DOI":"10.2307\/2344317"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00255-2"},{"key":"R21","unstructured":"Wilson W, Neelapu S, Rosenwald A, et al: Idiotype vaccine and dose-adjusted EPOCH-rituximab treatment in untreated mantle-cell lymphoma: Preliminary report on clinical outcome and analysis of immune response. Blood 102:11,2003,  (abstr 358)"},{"key":"R22","unstructured":"Hiddeman W, Unterhalt M, Dreyling M, et al: The addition of rituximab to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood 100:92a,2002,  (suppl 1, abstr 339)"},{"key":"R23","unstructured":"Levine AM, Espina BM, Mohrbacher LH, et al: Fludarabine, mitoxantrone, and Rituxan: An effective regimen for the treatment of mantle cell lymphoma. Blood 100:361a,2002,  (suppl 1, abstr 1399)"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3363"},{"key":"R25","unstructured":"Zelenetz AD, Donnelly G, Halaas J, et al: Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab\/iodine I131 (I-tositumomab) followed by CHOP chemotherapy results in a high complete remission rate. Blood 102:11,2003,  (abstr 1477)"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2476"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11838"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04140.x"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00093.x"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402406"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1518"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-10-855"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.113"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf042"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.01.1825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:39:45Z","timestamp":1653511185000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.01.1825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":35,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["10.1200\/JCO.2005.01.1825"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.01.1825","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}